摘要
支气管哮喘(哮喘)是很常见的慢性呼吸道疾病,在全球范围内患病率逐年升高。虽然重度哮喘只占全部哮喘的5%~10%,但是我国重度哮喘患者人口基数庞大,所占比例不容小觑。重度哮喘对患者健康状态的严重影响及导致的沉重疾病负担,应引起临床医生及决策者的高度重视。近年来以生物制剂为基础的个体化靶向治疗得到了极速发展,生物靶向治疗提高了患者生活质量,为重度哮喘患者带来新的获益。本文通过回顾近年国内外最新指南及研究进展,对重度哮喘的流行病学、疾病负担、我国临床特征及靶向治疗现状等方面进行综述,以期为重度哮喘的诊治及公共卫生政策的制订提供参考。
Bronchial asthma(asthma)is a very common chronic respiratory disease,and its prevalence is increasing year by year around the world.Although severe asthma accounts for only 5%-10%of all asthma,the large population base of patients with severe asthma in China is huge,and the proportion and cannot be underestimated.The serious impacts of severe asthma on the health status of patients and the resulting heavy disease burden should arouse the attention of clinicians and decision makers.In recent years,individualized targeted therapy based on biologics has developed extremely rapidly,and biologically targeted therapy has improved the quality of life of patients and brought new benefits to patients with severe asthma.Through retrospecting the latest guidelines and research progress at home and abroad in recent years,this paper reviews the severe asthma in terms of epidemiology,disease burden,clinical characteristics and current status of targeted therapy in China,with an aim to providing reference for the diagnosis and treatment of severe asthma and the formulation of public health policies.
作者
刘明明
张秀琴
LIU Mingming;ZHANG Xiuqin(Department of Respiration,the First Affiliated Hospital of Soochow University,Suzhou 215000,China)
出处
《中国现代医生》
2021年第29期188-192,共5页
China Modern Doctor
关键词
重度哮喘
疾病负担
表型
靶向治疗
Severe asthma
Disease burden
Phenotype
Targeted therapy
